Please login to the form below

Not currently logged in
Email:
Password:

Almirall/ Nycomed COPD co-branding deal

Almirall and Nycomed have entered into a co-branding agreement for the commercialisation of roflumilast, a once-daily tablet for patients with chronic obstructive pulmonary disease, in Spain

Almirall and Nycomed have entered into a co-branding agreement for the commercialisation of roflumilast, the once-daily tablet for patients with chronic obstructive pulmonary disease (COPD), in Spain.

Roflumilast is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor, and the first oral anti-inflammatory treatment for COPD.

Nycomed will receive an undisclosed upfront fee from Almirall, who will be exclusively promoting a second brand of roflumilast in Spain.

Luciano Conde, Almirall's chief operating officer, said: "This product, an entirely new class of treatment, has a strong strategic fit in our business and is fully complementary with other bronchodilator treatments in COPD such as our R&D product aclidinium bromide which is expected to be filed this year.

"We expect roflumilast to generate sales as of this year and could become one of Almirall's key products in the mid-term," he added.

5th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics